The Commission of the Ministry of health recommended the inclusion of nusinesses (trade name Spinrate), designed to treat spinal muscular atrophy, the list of vital and essential drugs (EDL) for the next year.
“For most, the decision is made”, — quotes RIA Novosti words of the Director of the Department of drug supply and regulation of medical products circulation Elena Maksimkina. Maksimkina said that the Commission is only a recommendation, the final decision will be made by the government.
Currently nusinesses is the only drug for the treatment of spinal muscular atrophy – a genetic life-threatening disease in which gradually lost motor functions. Earlier, Deputy Prime Minister of Russia Tatiana Golikova proposed to Russian President Vladimir Putin to consider options for funding the procurement of nomineren. Due to the high cost Spinnaz many regions may not be able to provide them with the patients: the average cost of a course of the drug in 2019 amounted to RUB 47.5 million in the first year, and 23.7 million rubles in the second year.
In addition to nomineren on the Russian market may soon receive the gene therapy of SMA of nazemnogo ibuprofen. Now the Ministry of health is considering a dossier for registration of the drug. In case of successful registration on the territory of RF drug nazemnogo ibuprofen (Solvency) is indicated for the treatment of patients with spinal muscular atrophy (SMA) with bi-allelic mutation in the gene SMN1 and a clinical diagnosis of SMA 1-type, as well as patients with SMA with bi-allelic mutation in the gene SMN1 that have up to 3 copies of the gene SMN2, inclusive, including patients without clinical appearances.